Overview

Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma

Status:
Withdrawn

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the highest tolerated dose of rAd.CD40L (also called ISF35) when given with pembrolizumab to patients with melanoma. Researchers also want to learn if the highest tolerated dose of ISF35 and pembrolizumab can help to control the disease. The safety of this drug combination will be also be studied.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Memgen, LLC

Treatments:

Pembrolizumab